多面性音乐疗法治疗痴呆症抑郁症:随机对照试验的网络元分析
Berne Ting1, Daniel Tzu-Li Chen2,3,4,5, Wei-Ti Hsu5,6
1Ph.D. Program for Aging, College of Medicine, China Medical University, Taichung 40402, Taiwan.
European journal of investigation in health, psychology and education
|February 23, 2024
概括
积极的音乐治疗与歌唱相结合,可显著降低痴呆症患者的抑郁症状. 这种音乐治疗方法有效且耐受性良好,为痴呆症护理提供了一个有前途的选择.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 抑郁症状是痴呆症患者常见且令人痛苦的并发症.
- 目前用于痴呆症抑郁症的药物治疗方法的疗效和潜在副作用有限.
- 非药物干预,如音乐治疗,越来越多地被探索为管理抑郁症在这个人群中.
研究的目的:
- 系统地评估和比较各种音乐治疗干预措施的有效性,以减少痴呆症患者的抑郁症状.
- 评估不同音乐治疗方式对退学率的影响,与标准护理相比.
- 确定最有效的音乐治疗方法来改善痴呆症抑郁症.
主要方法:
- 进行了网络元分析,合成了14项随机对照试验 (RCT) 的数据,涉及1080名参与者.
- 干预措施包括积极的音乐治疗,音乐倾听,节奏音乐治疗,唱歌和定制的音乐干预.
- 主要结局是抑郁症状的变化 (标准化平均差异 (SMD)),次要结局是退学率.
主要成果:
- 与歌唱相结合的活跃音乐疗法在减少抑郁症状方面表现出最大的有效性 (SMD = -0.89,95% CI: -1.48至 -0.30).
- 仅仅听音乐的效果显得不那么明显 (SMD = -0.26,95% CI: -0.71到0.20).
- 在音乐治疗干预和标准护理之间没有观察到学率的显著差异,这表明具有良好的可行性和可接受性.
结论:
- 积极的音乐治疗包括唱歌是缓解痴呆症患者抑郁症状的高效策略.
- 群体歌唱可能促进的增强社会互动可能有助于其治疗效益.
- 这些发现支持将积极的音乐治疗与唱歌整合到痴呆症护理方案中,这需要进一步的临床研究和应用.
更多相关视频
04:29Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.6K
11:50Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit
Published on: January 7, 2020
26.4K
相关概念视频
Depressive Disorders: MDD and Dysthymia
136
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
136
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Depression: Overview
244
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
244
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Depressive Disorders: Etiology
102
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
102
Antidepressant Drugs: MAOIs and Other Agents
230
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
230
